Literature DB >> 17038135

Pacemaker longevity: are we getting what we are promised?

Janek Senaratne1, Marleen E Irwin, Manohara P J Senaratne.   

Abstract

BACKGROUND: Although pacemaker manufacturers provide projections on longevity, these projections cannot be relied upon due to the assumptions of output parameters being far in excess of those programmed in clinical practice.
OBJECTIVE: The purpose of this review was to compare the actual longevity to the calculated longevity of pacemakers based on battery cell characteristics taking into account individual programmed parameters, mode, degree of usage, and percent pacing. This was also compared to the manufacturers' own projected longevities.
METHODS: Patients who had a pacemaker replaced between 1998 and 2003 were included (n = 124). Cell characteristics were obtained from manufacturers and programmed parameters were obtained at each visit. Stepwise calculations were done for each visit to find current drain during each interval, and then were used in a weighted average to find the total average lifetime current drain. This was subsequently used to find a calculated longevity for each pacemaker to be compared to the actual longevity observed.
RESULTS: The pacemakers lasted 491+/-92 days (mean+/-SEM) less than calculated. There was also a difference between dual- and single-chamber devices (though not statistically significant). Moreover, it was found that there were significant differences between manufacturers.
CONCLUSIONS: There appears to be a significant discrepancy between calculated and actual longevities, confirming that battery depletion occurs earlier than expected. This suggests that current drain expended for ancillary functions may be considerable. Another factor may be pre-implantation drain. Vigilance with programming of outputs, modes, sensors, heart rates, and ancillary functions could potentially extend longevity and postpone/obviate the need for costly repeat surgery with its attended risk of complications. Furthermore, the differences between manufacturers seem to parallel the clinical impressions.

Entities:  

Mesh:

Year:  2006        PMID: 17038135     DOI: 10.1111/j.1540-8159.2006.00497.x

Source DB:  PubMed          Journal:  Pacing Clin Electrophysiol        ISSN: 0147-8389            Impact factor:   1.976


  5 in total

1.  Complications and lead extraction in cardiac pacing and defibrillation.

Authors:  F Bracke
Journal:  Neth Heart J       Date:  2008-10       Impact factor: 2.380

2.  Cell and gene therapy for arrhythmias: Repair of cardiac conduction damage.

Authors:  Yong-Fu Xiao
Journal:  J Geriatr Cardiol       Date:  2011-09       Impact factor: 3.327

3.  Early performance of a miniaturized leadless cardiac pacemaker: the Micra Transcatheter Pacing Study.

Authors:  Philippe Ritter; Gabor Z Duray; Clemens Steinwender; Kyoko Soejima; Razali Omar; Lluís Mont; Lucas V A Boersma; Reinoud E Knops; Larry Chinitz; Shu Zhang; Calambur Narasimhan; John Hummel; Michael Lloyd; Timothy Alexander Simmers; Andrew Voigt; Verla Laager; Kurt Stromberg; Matthew D Bonner; Todd J Sheldon; Dwight Reynolds
Journal:  Eur Heart J       Date:  2015-06-04       Impact factor: 29.983

4.  Trends in service time of pacemakers in the Netherlands: a long-term nationwide follow-up study.

Authors:  L M de Vries; M J G Leening; W A Dijk; C A M Hooijschuur; B H C Stricker; N M van Hemel
Journal:  Neth Heart J       Date:  2017-08-02       Impact factor: 2.380

Review 5.  TAVR: A Review of Current Practices and Considerations in Low-Risk Patients.

Authors:  Jenna Spears; Yousif Al-Saiegh; David Goldberg; Sina Manthey; Sheldon Goldberg
Journal:  J Interv Cardiol       Date:  2020-12-24       Impact factor: 2.279

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.